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Tanzania
A B S T R A C T
Misoprostol has during the past few years become an important obstetric drug used for different purposes both
within and outside hospitals in Tanzania. In this paper, we analyze how misoprostol is perceived, accessed and
used off-label as an abortion drug in the city and region of Dar es Salaam. The study took place in Dar es Salaam's
three districts from July to November 2015, and had a qualitative explorative approach. We carried out in-depth
interviews (42) with the following main categories of informants: women having undergone medical abortion
(15), health care workers with experiences from post abortion care (16) and drug vendors (11). Focus group
discussions (10) were carried out with young women. A client simulation study was carried out in 64 drugstores
across Dar es Salaam assessing the availability of misoprostol and the advice given concerning its use. In ad-
dition, shorter qualitative interviews were carried out with representatives of NGOs and public agencies working
with sexual and reproductive health issues (17). Our findings reveal that in Dar es Salaam, misoprostol is well
known, available and accessed for abortion purposes through drugstores and health providers. Women tend to
prefer misoprostol over other abortion methods since it allows for a private, low-cost, safer and less un-
comfortable abortion experience. But, while misoprostol facilitates women's agency in the process of seeking
abortion, a series of obstacles shaped by a restrictive abortion law and an unregulated pharmaceutical market
hinder its safe use. Central obstacles are profit-seeking providers, suboptimal user instructions and poor provider
follow-up. In the discussion of the material we draw upon Van der Geest, Hardon and Whyte's concept of the
‘social life of pharmaceuticals’ and indicate the ways in which misoprostol acts as an agent of change in the
social relations connected to abortion.
1. Introduction
“Because everybody now knows what the pills (misoprostol) do,
everybody is selling them, at their own prices, because they know
people need them. If you want to have an abortion, you will buy
them no matter how much they cost.”
The demand for misoprostol for abortion purposes is increasing
globally and the city of Dar es Salaam in Tanzania is no exception. The
excerpt above, from a focus group discussion among university students
in Dar es Salaam, speaks to the growing demand for and access to
misoprostol in the city. This paper seeks to gain a better understanding
of the potentials and challenges implied by the presence of an abortion
drug within a legally restrictive context such as Tanzania.
When misoprostol was registered as a prescription drug in Tanzania
in 2007 its intention was to treat and prevent bleeding after delivery
(Bixby center et al., 2011). However, misoprostol has since then re-
portedly been accessible in pharmacies without prescription, including
to women seeking abortion. Tanzanian pharmacies are known to dis-
pense drugs without prescriptions (Kagashe et al., 2011), yet, an
abortion drug makes for a special case as pregnancy termination is
highly restricted by law in Tanzania. The penal code dictates sentences
from three to 14 years for those who in some way or other facilitate an
abortion when a pregnancy does not threaten a woman's life (Tanzania
Penal Code, 1981). In Tanzania prosecutions related to abortion are
considered rare, yet the common idea is that abortion is illegal and
abortions are by and large carried out clandestinely (Keogh et al.,
2015). While misoprostol has been recognized as a safer abortion
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alternative for women in countries where abortion services are re-
stricted (Zamberlin et al., 2012; Ramos et al., 2015; Dzuba et al., 2013;
Barbosa and Arilha, 1993), there is in Tanzania concern about the
quality and safety of care provided alongside its sale when not su-
pervised by medical authorities (Kamuhabwa and Ignace, 2015;
Cartwright et al., 2013).
1.1. Background
The fact that misoprostol finds its way to Tanzanian women with
unwanted pregnancy should not come as a surprise. Already in the
1980s, misoprostol went from being an anti-ulcer medication to a
popular abortifacient among Latin-American women in lack of legal
abortion services (Barbosa and Arilha, 1993). Over the past few decades
misoprostol has become increasingly available globally (Fernandez
et al., 2009) and is today a drug that cannot be overlooked when dis-
cussing abortion in any country. The drug can be purchased over the
internet from pharmaceutical companies without prescription (Murtagh
et al., 2018) and international women's rights organizations have found
ways of bypassing national regulations using telemedicine to provide
information about the drug and securing its distribution (Gomperts
et al., 2008). The global spread of misoprostol is an expression of the
advancements of medical abortion (abortion by use of drugs) since the
introduction of the first abortion drug mifepristone (RU-486) in the
1980s. While still largely limited to first trimester abortions, medical
abortion is in a number of countries increasingly replacing conventional
surgical procedures as a non-invasive, safe and acceptable abortion
method (Raymond et al., 2013; Kulier et al., 2011). The simplicity of
administering a pill, rather than performing surgery, has importantly
allowed responsibility for safe abortion services to be transferred to
lower level health workers (Barnard et al., 2015), and even for women
to induce early abortions at home through guidance from health pro-
viders (Iyengar et al., 2016; Lokeland et al., 2016). Medical abortion is
most efficient when misoprostol is part of a two-drug regimen alongside
mifepristone. However, misoprostol - which is a heat stable, cheaper
and more available drug than mifepristone – is also 85–90% effective
when used correctly as a single drug (Tang et al., 2013; Harper et al.,
2007). Acknowledging misoprostol's potential as a global abortion
drug, the World Health Organization (WHO) issued guidelines for
abortion by the use of misoprostol alone in 2012, all the while stressing
the importance of access to PAC (post-abortion care) services for
treatment of potential complications, such as incomplete abortion
(Tang et al., 2013). In a number of countries, misoprostol-only abor-
tions have been welcomed for their relative safety, effectiveness and
convenience compared to other abortion alternatives (Zamberlin et al.,
2012; Ramos et al., 2015; Iyengar et al., 2016). Studies from Latin
American countries indicate that the incidence of severe complications
from unsafe abortion falls when misoprostol replaces other self-induced
abortion methods (Dzuba et al., 2013). The much cited case of Uruguay
has demonstrated how misoprostol has been successfully applied as a
public health tool to reduce harm from unsafe abortion even under
strict legal regulations (Briozzo, 2016).
In Tanzania, a wide range of methods for self-induced abortion have
been reported, including concentrated teas, washing detergents, wood
ashes, antimicrobial drugs in high doses or uterine insertion of sharp
objects (Norris et al., 2016; Brown et al., 2013; Bangser, 2010; Plummer
et al., 2008; Rasch and Kipingili, 2009; Rasch et al., 2014). Several of
these methods are associated with severe complications (Rasch and
Kipingili, 2009). “Traditional” providers have been known to assist
women with abortion through various methods, but illegal abortion
services have also been accessible through health professionals, most
often by the use of surgical procedures such as dilation and curettage (D
&C) or manual vacuum aspiration (MVA) (Rasch and Kipingili, 2009).
Reliable estimates of induced abortion rates are almost impossible to
obtain in East African contexts, but what is available of hospital-based
data indicate a rate of 36 induced abortions per 1000 women in
Tanzania (Keogh et al., 2015). This is a relatively similar figure to es-
timates of the average incidence of abortion in other East-African
countries and indeed in the African region as a whole (34 per 1000
women) (Sedgh et al., 2016). It has been suggested that as much as a
quarter of the Tanzanian maternal mortality ratio (556 per 100,000 live
births) may be abortion related (Sorensen et al., 2010; Mswia et al.,
2012; TDHS-MIS, 2016), and that 67,000 hospitalizations annually are
caused by complications of unsafe abortions (Sorensen et al., 2010;
Mswia et al., 2012; Rasch et al., 2000). Despite the uncertainty related
to these figures, there is no doubt that unsafe abortion is a severe threat
to women's lives and health in Tanzania and implies an enormous
burden on a hard pressed health system. While the Tanzanian autho-
rities have recognized the magnitude of the problem, the response has
been both ambiguous and limited. As a response to public health ad-
vocacy (backed by international development goals such as the MDGs),
a number of programs have been launched to improve universal access
to family planning services (UN Foundation/Family Planning 2020,
2018). Non-discriminatory post-abortion care services (PAC) have also
been implemented across the country, aiming to offer the same emer-
gency care to women who have terminated their pregnancies in-
tentionally as to the ones who have suffered unintended miscarriages
(Keogh et al., 2015). As a response to international human rights ad-
vocacy, Tanzania has moreover ratified the Maputo Protocol, an
agreement aiming to strengthen African women's rights in general and
sexual and reproductive rights in particular, including improved access
to safe abortion services (“Protocol to the African Charter on Human
and Peoples’ Rights on the Rights of Women in Africa, Art. 142c,
Adopted July 11, 2003, 2nd African Union Assembly, Maputo,
Mozambique ratified Mar. 3,” 2007). However, rather than expanding
the ground on which abortion may be legally obtained as implied by the
Maputo Protocol, the current government has suggested more severe
sanctions on doctors performing illegal abortions (Makoye, 2016). In
Tanzania, Christian and Muslim institutions operate within strong
moral regimes on sexuality and reproduction. The implications are,
among others, a lack of contraceptive education in Tanzanian schools
and lack of re-entry possibilities for girls who drop out of school due to
pregnancy (Center for Reproductive Rights, 2013). As has been shown
in studies from other Sub-Saharan contexts, induced abortion is heavily
stigmatized as it is closely associated with non-marital sex (Bleek, 1981;
Johnson-Hanks, 2002; Rossier, 2007; Stiles et al., 2015) and perceived
of as killing an unborn child (Sambaiga et al., 2019). In Tanzania,
fertility control - including abortion - is thus a question of moral politics
where public health and rights-to-health arguments may fall short.
There is a vast number of stakeholders operating with opposite abortion
related positions and agendas in Tanzania (Sambaiga et al., 2019).
Morgan and Roberts (2012) argue that reproductive governance is an
arena that at all time is cramped with actors, such as politicians, re-
ligious leaders, international development promoters, public health
promoters, industries, activists, health workers, product vendors or
women themselves. It is hence a complex and highly ambiguous en-
vironment that shape the conditions under which misoprostol is ac-
cessed by women in Dar es Salaam.
Van der Geest, Hardon and Whyte have studied medicines as social
and cultural phenomena (Van der Geest et al., 1996; Whyte, 1992).
Drawing upon Appadurai's notion the “social life of things” (Appadurai,
1986), they argue that studying pharmaceuticals is particularly useful
when seeking knowledge about processes of globalization, localization
and social transformation (Van der Geest et al., 1996). As an illustrative
example, studies from Latin-America have powerfully demonstrated
how misoprostol has been a change-maker in women's access to safe
abortion, in the process instigating diverse forms of social transforma-
tion. This includes both improvements in reproductive health indicators
as well as policy changes in access to legal abortion services (Briozzo,
2016; Kulczycki, 2011). While the global spread of misoprostol as an
abortion drug may be understood both as a driver and result of glo-
balization, the manner in which the drug is perceived, accessed and
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managed is context dependent. In Sub-Saharan Africa, where mis-
oprostol has been available for a far shorter period of time than in Latin
America, there are to date few studies about how it is conceptualized
and used as an abortion drug. The overall aim of this study was to
enhance knowledge about misoprostol and its potential to improve safe
abortion care in Tanzania and in similar settings. Clarke and Montini,
who have studied the development and globalization of mifepristone
(the first official abortion drug), have demonstrated that discourses on
new medicines vary significantly depending on the outlook and stakes
of the involved actors (Clarke and Montini, 1993). They have called for
a focus on actors differently situated in relation to the medicine in
question, including ‘downstream users and consumers’ (Clarke and
Montini, 1993). Inspired by Van der Geest, Hardon and Whyte's studies
on pharmaceuticals as social phenomena (Van der Geest et al., 1996;
Whyte, 1992) and by Clarke and Montini's call for downstream studies
of discourses surrounding medicines, we studied how misoprostol is
perceived, accessed and used on the ground in Dar es Salaam. In the
process we explored how the use of misoprostol as an abortion drug is
shaped by and in turn shape local practices and social relations.
2. Materials and methods
The material on which this article is based was collected during an
ethnographic fieldwork carried out from the middle of July until the
end of November 2015. Considering how misoprostol is a relatively
recent drug on the market in Tanzania, and likely to be more prevalent
in urban than in rural areas, Dar es Salaam region was chosen as the
study site. All three districts of the region of Dar es Salaam (Kinondoni,
Ilala and Temeke), including urban and suburban areas, were part of
the study site. With a population of almost five million inhabitants, Dar
es Salaam is Tanzania's largest city and an economic hub to which
young people from all parts of the country come to study and work.
While the induced abortion rate for this zone (the Eastern zone) of the
country is estimated to be below the national average (at 23.9 per 1000
women), the estimated number of women who perform an abortion and
do not seek post abortion care services is suggested to be higher than
the national average (Keogh et al., 2015). The reason for lower rates of
PAC may be linked either to fewer abortions with complications or to
more complications left untreated. Due to their special vulnerability to
unsafe abortion, the main focus of our study was placed on the ex-
periences of young women. In an attempt to untangle a variety of ex-
perience with misoprostol as an abortive drug, we moreover ap-
proached health providers and drug vendors as key categories of
informants (Table 1).
2.1. Informants and recruitment
During the fieldwork, the researchers had informal and formal
conversations with a large number of individuals both with and without
concrete experience with misoprostol.
Young women who had used drugs to induce an abortion (15) were
recruited for in-depth interviews (IDIs) by health personnel working
with PAC services. To gain a broader and more nuanced perspective on
unwanted pregnancy and fertility control including abortion, we also
included young women who had not sought PAC after medical abortion
(7 out of 15). These women were recruited through personal contacts of
the research team and through health workers' contacts. Although we
cannot be certain that it was in fact misoprostol that had been used for
abortive purposes, it does seem likely based on reported brand names,
dosages and administration routes. In the paper we will use the term
‘misoprostol’ when we are certain about the specific pharmaceutical
referred to, otherwise the term ‘medical abortion’ will be used.
A group of young women, recruited on the criteria of gender and
age, but irrespective of concrete experience related to abortion, were
invited to focus group discussions (10 groups in total). To get in touch
with the latter category of women we received help from Street Offices
(the most local public offices in Dar es Salaam) and from WhatsApp and
Facebook groups.
Health workers (16) with diverse professional backgrounds were
also recruited for IDIs. They were identified by the facility adminis-
trations and colleagues based on their experience with PAC, and were
interviewed at the health facilities. This category of informants pro-
vided information on health-related dimensions of medical abortion,
including its provision.
Drug vendors (11) with diverse professional backgrounds were re-
cruited for IDIs through direct questions of participation. In addition to
more than 200 registered pharmacies in Dar es Salaam, several hundred
‘drug dispensing outlets’ operate without permission to sell prescription
drugs, including misoprostol (Kamuhabwa and Ignace, 2015). We refer
to these outlets as ‘medical shops’, while ‘drugstores’ include both
pharmacies and medical shops. ‘Drug vendor’ refers to anyone working
in a drugstore. The vendors interviewed operated in different categories
of drugstores at different locations across the city, including busy and
peripheral areas, low- and high-income areas. Due to many rejections,
recruitment of drug vendors was slow. We thus decided to include a
client simulation study, which involved entering pharmacies and
medical shops in different areas across Dar es Salaam (64 in total)
asking for misoprostol without prescription. The intention was to ex-
plore drug vendors' knowledge about medical abortion as well as to
assess the availability and access of misoprostol. As much information
as possible was written down after the simulation visits, including the
Table 1
An overview of the qualitative methods applied and of the study participants.
Method of data collection Number and categories of participants
42 in-depth interviews (IDIs) 15 women≤ 25 years having had medical abortion after unwanted pregnancy, of whom 8 had sought PAC
16 health workers (3 gynecologists, 6 medical doctors, 4 clinical officers, 3 midwives and 1 nurse) from 12 health facilities (4 dispensaries, 2
clinics, 2 health centers and 4 hospitals) of which 7 were private
11 drug providers (6 pharmacists, 1 clinical officer, 2 laboratory technicians, 1 nurse and 1 nurse assistant) recruited from 7 pharmacies
and 4 medical shops
10 focus group discussions (FGDs) 7 groups with a total of 54 young women 15–25 years (recruited from three different low-income areas with age and gender as the only
criteria of inclusion)
3 groups with a total of 21 female college and universities students studying and/or residing in Dar es Salaam (recruited with gender as the
only criteria of inclusion)
17 (shorter) qualitative interviews 10 representatives from NGOs (of which 6 were INGOs) with a focus on sexual and reproductive health (SRH)
3 representatives of district authorities with a focus on SRH services
4 representatives of ministry authorities with a focus on SRH services and/or drug policies and pharmaceutical practices
Client simulation 64 drugstores (37 pharmacies and 27 medical shops located differently in the city – center/periphery, low-income/high-income areas, close
to/far from hospitals.)
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vendor's response, prices, instructions (if any), products, etc.
Finally, we carried out qualitative (shorter) interviews with re-
presentatives of governmental agencies and national and international
organizations concerned with reproductive health (17) in an attempt to
increase our understanding of how the presence of misoprostol and
medical abortion play into politics, activism and public health work in
Tanzania.
2.2. Research and ethical approvals
The study was granted ethical approval by the Norwegian
Committees for Medical and Health Research Ethics (2015/79d) and
from the National Health Research Ethics Sub-Committee in Tanzania
(NIMR/HQ/R.8a/Vol.IX/1970). Research permit was further granted
by the Tanzanian Commission of Science and Technology (2015-203-
NA-2015-191), from district medical officers in the three districts of Dar
es Salaam region, as well as from all recruitment site administrations.
Oral and written informed consent was sought from all participants
except during the client simulation. All IDI- and FGD participants re-
ceived a compensation for time and transport of between 5000 and
15,000 Tanzanian shillings/TSH (approx. 2.5–10 USD) depending on
the time and inconvenience of their participation.
2.3. Data collection
The large majority of the interviews with health professionals, drug
providers and organization representatives were carried out in English
by the first author. The FGDs were mediated in Swahili by one of the
research assistants. The IDIs with the young women were similarly
carried out by a research assistant in Swahili in a location chosen by the
participant. Two of these interviews were carried out by telephone.
Except for the women who were recruited through PAC services who
seemed shy and reluctant to speak at length, the study participants
eagerly engaged in the conversations about unwanted pregnancy and
medical abortion. All interviews and focus group discussions were
audio recorded. The questions in the interview guides and the questions
raised in the client simulation study flexibly guided the conversations,
and evolved during the course of the fieldwork, allowing central
emerging issues to be further explored. Approximately half of the client
simulations were performed by the first author and the other half by
two local assistants. Although the first author is of European origin and
speaks rudimentary Swahili, no systematic differences in response were
noted from the pharmacy staff. Three young Tanzanian female research
assistants assisted the first author in the collection, transcription and
interpretation of the data.
2.4. Analysis
The analysis of the material took place continuously while in the
field, implying a reflection on emerging findings and new questions
arising. The translation from Swahili transcripts or audio tapes to
English took place during and after the closing of the fieldwork. After a
thorough read-through of all the data, we performed a post-fieldwork
Content Analysis as defined by Patton (2015). Using NVIVO software,
we inductively coded the full material, and systematically categorized
the coded material in themes related to the process of either needing,
choosing, seeking and carrying out a medical abortion. The triangula-
tion of data collected through the use of different data collection
methods (informal conversation, IDIs, FGDs and the simulation study)
and from the different categories of informants implied that a sub-
stantial material was available for cross checking and to detect emer-
ging themes and patterns as well as ambiguities and contradictions. For
instance, the accounts from the young women, the drug vendors, the
health workers, the NGO employees and from the simulation study
provided diverse perspectives on the question of access to medical
abortion and simultaneously led to a more comprehensive
understanding of the access situation of abortion in Dar es Salaam.
2.5. Methodological reflections
Abortion is both sensitive and illegal in Tanzania, and a study into
this issue will thus necessarily have shortcomings. It is likely that some
information presented to the researchers was censored, skewed or ex-
aggerated. We should be particularly aware of the possibility of under-
reporting among drug vendors and health workers engaged in illegal
provision of medical abortion. It is moreover likely that the data col-
lection and analysis was influenced by the main researcher's back-
ground as a European medical student. Considering the sensitivity of
the research topic - and our query into clandestine activity - we posi-
tioned ourselves as an ‘international, university-based team’ detached
from the Tanzanian authorities and control apparatus. While we were
obviously not able to level out the differences between ourselves and
the study participants, we believe it may have aided the research pro-
cess with the young women that all the interviewers - including the first
author - were young female students, and that to the extent possible the
interviews with the women took place removed from health facilities
and academic offices. In addition, our approach to avoid distorted in-
terpretations was to include participants differently situated vis-à-vis
the study topic (source triangulation), to use different methodological
approaches (methods triangulation) and to stay for an extended period
of time in the field while trying to meet our informants as openly as
possible.
3. Findings
We have grouped the study findings into three main themes: How
misoprostol was considered a commonly known, accessible and much
sought-after drug in Dar es Salaam; how the medicine was perceived of
as a relatively private, simple, natural and safe abortion method; and
finally, how accessing misoprostol was seen to involve a risk of having
to deal with opportunistic vendors, poor instructions, limited follow-up
and uncertain access to emergency care in case of an incomplete
abortion.
3.1. “Miso is common” - known, accessible and in demand
The majority of our study participants considered misoprostol a
commonly known drug for abortion in Dar es Salaam. Most of the
women participating in focus group discussions reported knowing
someone, directly or indirectly, who had aborted using ‘miso’ – the
common term used to refer to the drug. They believed that ‘miso’ was
today the most common abortion method in their community and had
considerable knowledge about access locations, prices and doses typi-
cally used. Most had learned about the drugs from friends, others from
doctors, pharmacists, organizations or from web pages or social media.
Some had even learned about it overhearing discussions in the street or
in hair saloons: “Sundays, when we're in a hair dressing saloon - that's
where you find topics like that one.” (Woman, 24 years, IDI) Both health-
and pharmacy workers commented on how not only clients, but friends,
family or other acquaintances were addressing them personally with
questions about medical abortion. An FGD participant explained:
“When it comes to these drugs for abortion, it is not that people are fighting
it. You can (even) find some places that teach about these drugs. They have
seen that if they do not teach, then … There are more complications when
people use ‘neem’ (a herb) or other drugs.”
The women participating in our study shared the impression that
these abortion drugs could be obtained in some way or other - either
through pharmacies, medical shops or health facilities. The client si-
mulation confirmed that misoprostol could be purchased across Dar es
Salaam. In 37 of the 64 visited drugstores vendors were willing to sell
misoprostol without prescription. A few stores also sold combinations
of misoprostol and mifepristone. The drugstore workers we interviewed
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had clearly noticed a demand for medical abortion drugs. A clinical
officer running his own medical shop just outside the city reportedly
received misoprostol customers four to ten times a week: “They know
misoprostol nowadays. They now announce that: Eh, a woman, somebody,
she used a drug known as misoprostol. Do you have it?” Customers would
often come without prescriptions, and some vendors would admit to
dispensing the drug in such cases - mostly for the sake of business, but
also because customers could be familiar locals or that they presented
challenges that the vendor could relate to. A nurse working in a medical
shop put it like this: "I sell the drug. Firstly, I know that it's a sin, I'm
Christian and I know that. Secondly, I know that it's against the law. But, I
sell the drug because I'm a mother and I know how it is when you have a
young child and then you have a pregnancy again. I feel sorry for them. I
wouldn't want that to happen to me either. And for the young girls, they have
parents at home. Sometimes I give them (the drug) because I wouldn't want
them to have problems where (the place) they will go to terminate the
pregnancy." According to drug vendors, most misoprostol customers
were young women, typically in their teens or early twenties, but there
was some variation. While all drug vendors that we interviewed had at
some point been approached by customers in search of medical abor-
tion, demand was reported more frequent in drugstores located in what
was considered low-income areas.
Young women generally considered misoprostol relatively afford-
able when accessed through drugstores: “It's cheap. It's different from the
hospital. So more people use tablets!” (Woman, 20 years, IDI) The price
for misoprostol (per abortion) typically ranged between 15,000 and
35,000 TZS (approximately 5–12 USD). While this was considered more
expensive than other self-induced methods (like teas or detergents), a
doctor performing surgical abortion might ask for anything from
30,000 to 250,000 TZS (approximately 10–85 USD), depending on the
facility. However, according to our participants, a range of health
workers: “doctors, nurses, even medical attendants and laboratory techni-
cians” had also started to offer medical abortion. Though reportedly
most accessible in private facilities, medical abortion could also be fa-
cilitated through public hospitals and dispensaries. This was confirmed
during interviews with health workers, who either explained that they
were providing medical abortions themselves or knew colleagues who
did. Some doctors preferred providing medical abortion because it was
the method preferred by women and could be done privately. Other
doctors explained that they still preferred the conventional surgical
methods, primarily for economic reasons, as they earned more from
such procedures. Secondly, the risk of an incomplete abortion was
perceived as higher by the use of drugs than surgery. Despite the fact
that we encountered clinicians who carried out abortion both in private
and public facilities, women commented that it was difficult to identify
these health providers when in need without prior knowledge or con-
nection due to the secrecy surrounding the procedure. In colleges and
universities, students explained that they would at times serve as links
between patients and doctors or they would even provide misoprostol
to co-students themselves: “Once you get pregnant you will know all of
those places and the ones who are selling those drugs. You will have their
contacts as well as doctor's contacts. You can even find students who are
agents for these doctors and they will direct you to them as they know who
are good at this job.” (Student, 21 years, FGD).
3.2. “It's your secret” – more private, simple and safe
Privacy was considered key when seeking abortion. Pharmacists
explained that customers often approached them only showing a note
or a mobile screen reading ‘miso’. Others would quietly explain their
situation in hope of awaking the vendor's sympathy, while others again
would send friends or boyfriends to negotiate on their behalf. “It's dif-
ferent if I go to the pharmacy and talk to the pharmacists. They will un-
derstand what I need, unlike going to the hospital and telling the doctor.
Then it won't be my secret anymore.” (Student, 22 years) Some women
pointed out how doctors might try to convince you to keep the baby,
causing a sense of guilt and uncertainty, as exemplified by a student's
comment: “You find you can go to the doctor and instead of being given that
medicine you start being counselled to keep it and people don't like coun-
selling. They will ask you if you will keep the pregnancy. ‘Are you ready?’
Those are questions some girls are avoiding”. Going to the hospital
moreover often involved waiting time during which ‘someone you
know might see you’. Thus, buying misoprostol in pharmacies, using it
alone at home, one was more likely to avoid difficult confrontations and
questions.
While seeing a doctor was by most women considered the safest
option when terminating a pregnancy, many feared the methods that
were typically known to be used by doctors, especially the ‘metal in-
struments’ (the sharp curettage, sometimes called the ‘shovel’, ma-
koleo), and the procedure known as ‘flashing’ (manual vacuum aspira-
tion). Some women perceived surgical procedures to be both quick and
certain, yet they were concerned about pain, as these were known to
often be performed without anesthesia. The insertions of instruments
also caused worries about potential damage to the uterus, infertility,
infections, cancer and even death. Some informants retold stories about
surgical abortions performed outside of hospitals, at the back of phar-
macies, in small unregistered clinics or in guesthouses. “In the past years
our parents used to say that surgical abortion is dangerous because they use
sharp instruments, and the action of using metals will be in her mind. And it
is a sin, so she finds it better to use pills for abortion rather than surgical
abortion.” (Student, 22 years, FGD) In this context, misoprostol emerged
less like the scary abortion procedures women had often heard about
and pictured. It was pointed out that using misoprostol was more like
“starting a period”, a more “natural way” of having an abortion, which
also meant it was easier to cover up the symptoms. A student explained
“If I try to compare them with these other methods I see, the pills are better
because I don't see them unsettled like in the past. In the past if someone had
an abortion you would know, but nowadays you can't know. So I think it's
better.” (Student, 22 years).
Although some of the women disliked the idea of medical abortion
as it was known to at times cause a long process with pain and bleeding,
most expressed that when effective, it was known to cause few pro-
blems: “Those pills are very good, they have no side effects, and once you
use it, it cleans everything, all the dirt comes out. You do not suffer, no pain,
no nothing.” (Woman, 22 years, IDI) Meanwhile, many of the health
workers that we interviewed in different facilities believed that over the
last few years there had been a drop in critically ill patients seeking care
after abortion, along with a change in the commonly admitted com-
plications. This study did not provide numerical evidence, but health
workers with years of experience noted that compared to earlier, fewer
women were admitted with uterine perforations, infections or sepsis
after abortion. Instead, more were currently presenting with prolonged
bleeding from incomplete abortions or simply with normal symptoms of
an ongoing abortion, such as abdominal cramps and heavy but self-
limiting bleeding. They related these changes to the recent shift towards
medical abortion: “I think complications of abortions are getting better now,
especially in towns, because they don't use the unsterile instruments, they use
the medical way. I think the medical method is reducing complications. The
bleeding complications, they can be controlled. But sepsis - it's minimal. I
don't see a lot of sepsis now” (Health worker, IDI).
3.3. “It's a business” – opportunistic stakeholders, poor information and
incomplete abortions
Despite misoprostol's many perceived advantages, the process of
obtaining an effective and safe medical abortion was not perceived to
be without risks. In Dar es Salaam, misoprostol had opened up for new
stakeholders in the provision of abortion. Though not legally authorized
to sell misoprostol, smaller medical shops provided an alternative to
pharmacies. Some women explained that they preferred this option, as
they were less likely to be asked questions or demanded prescriptions.
However, some worried about low-quality or fake drugs: “The large
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pharmacies are where they have the original drugs and where you can get
instructions, but I have seen people avoid going to those. They go to the small
ones because they are very careful. They know it's illegal so they go there and
then google how to use them (the drugs).” (Student, 23 years, FGD) Some
drug vendors as well as health workers insisted that certain misoprostol
brands were effective while others were not. Moreover, misoprostol was
typically sold uncontained by boxes and without instruction sheets,
sometimes even without blisters. Without this basic packaging, mis-
oprostol is known to degrade and lose effect (Berard et al., 2014). A
pharmacist also commented that some vendors had kept on selling
batches of misoprostol past its expiration by simply remarking its dates,
and health workers were concerned that women could end up with
drugs that were in fact not misoprostol. Many women only knew mis-
oprostol as “abortion pills”, and even if they knew the name of the drug,
would they be able to differentiate misoprostol from other tablets?
Group discussions added substance to this concern as there was some-
times confusion between misoprostol and other strong drugs (such as
antibiotics) or contraceptive pills that were at times used to self-induce
abortion. Another worrisome problem with misoprostol was that the
pills were known to not work for everyone: “Some pregnancies are hard
to remove by pills. It doesn't matter how many pills you take, they don't come
off.” (Woman, 24 years, FGD) This caused uncertainty among women.
While some were aware of the drug's inherent failure rate, others
blamed opportunistic vendors: “I heard there are fake ones and original
ones, and everybody is selling them at their own price because they know this
is the deal nowadays. Everybody is looking for them.” (Student, 23 years,
FGD).
Another point of confusion was that of correct use. Knowledge
shared about misoprostol seemed largely based on trial and error. While
most drug vendors would not advise misoprostol if the pregnancy was
more advanced than nine weeks, among the ones we interviewed
(pharmacists included) only a minority had in-depth knowledge about
the usage of misoprostol. The most recent international guidelines for
safe interruption of pregnancy by the use of misoprostol advise 800 μg
vaginally or sublingually every 3 h (maximum three times within 12 h)
for first trimester pregnancies (Tang et al., 2013). In our study we found
that drug vendors most commonly recommended four pills (each of
200 μg) in a single dose with no repetition (usually two pills sub-
lingually and two vaginally), and sometimes only one or two pills. A
few vendors were aware of the twelve-pill regimen described above, but
some nonetheless recommended a lower dose, insisting that from ex-
perience fewer pills had proved effective without unnecessary pain and
bleeding. It was common to advise painkillers and a regimen of anti-
biotics after taking misoprostol to “clean up” the uterus. While the
latter does not correlate with WHO guidelines, it was a perceived as a
precaution against infection arising in case of incomplete abortion.
Having experienced women seeking help late in the process of in-
complete abortions, health workers were concerned about the amount
and quality of instructions women would get from drug vendors. A
clinical officer complained: “Because they're not qualified (the drug ven-
dors), they sell it like rice: “Take this and use it!” No more explanations.”
Another well-known problem was the shortage of pharmacists, who
often rotated between several pharmacies, and rarely met customers. In
some of our interviews, women explained their concern of not receiving
enough information about the procedure, especially about what to ex-
pect, how much one would bleed and for how long. Indeed, some drug
vendors explained that they preferred not to provide any instructions at
all, because they felt uncomfortable contributing more than necessary
to the abortion due to its illegality. A young pharmacist was instructed
by his employer: “She told us to not direct them on how to use it. You know,
it's illegal. (…) Someone might come and trick you. So, if they asked me
‘How do I use this medicine?’ I would tell them ‘I don't know’. We just gave
them the medicine.”
Virtually all our participants were familiar with stories from their
communities about women who had suffered illness or death either
from self-performed abortions or from abortions performed by quacks.
Even if it meant borrowing money from family or friends, some were
therefore willing and able to get the extra amount for a doctor to assist
them with a medical abortion. Medical abortion through private health
facilities reportedly cost several hundred thousand TZS. In the end, the
provider had power over the service and the price would “depend on his
greed”, as one young woman put it: “Because everybody now knows what
the pills do, everybody is selling them, at their own prices, because they know
people need them. If you want to have an abortion, you will buy them no
matter how much they cost.” (Student, 22 years, FGD) There were how-
ever also examples of lower costs when approaching public doctors.
One of our participants had approached a public dispensary and paid no
more than the regular consultation fee - less than a dollar - leaving with
a prescription for misoprostol, and was consequently able to purchase
misoprostol for 10,000 TZS (approximately 3 USD).
While medical assistance was perceived to be the safer option, we
found that even among health workers there was inconsistency about
the correct use of misoprostol. Reported doses at times seemed to be
confused with those for other uses of misoprostol (post-delivery
bleeding, induction of labor, incomplete abortion). A few select health
workers who reported having received formal medical abortion training
usually followed international recommendations. However, the same
health workers dispiritedly reported how their patients would return to
them having used only a fraction of the recommended dose, either
because the full dose was too expensive, or because friends or drug
vendors had advised them differently. Several clinicians also underlined
the difficulty of a proper follow-up. Because of the restrictive law, most
ended up merely handing out or prescribing the drugs. “Everyone who is
using it is practicing it secretly. That's why everyone will end up using what
he thinks is right, and what he thinks his patients will be safe with. But, if it
was legal - like when we are using misoprostol for missed abortion (in-
complete miscarriage) - when you make sure you follow the protocols well -
then it is a safe drug.” (MD, private hospital) Another health worker
similarly referred to the implications of the restrictive legal system
saying: “What I can say is that our government regulations are also hin-
dering the women to be open, and the sellers of drugs to give wide ex-
planation on how to practice safe abortion.” Adding to these challenges,
true access to post-abortion care was not always the case, as ex-
emplified in our study by participants who had suffered incomplete
abortions. One woman explained how, despite severe bleeding, she had
been denied treatment until she contacted family members who upon
arrival payed the doctor a sum several times that of the official PAC
costs. Another study participant had been sent from facility to facility
without receiving care until she finally ended up in a hospital with large
expenses that she could not cover without help from her family who
until then had known nothing about her pregnancy.
4. Discussion
What we encountered in Dar es Salaam indicates an increasing
availability of misoprostol and medical abortion within a context of a
highly restrictive but not strictly implemented law. We will argue that
access to misoprostol is shaped by already existing local and social
conditions, but that the drug simultaneously shapes new power rela-
tions and shifts control over fertility and abortion from legal, govern-
mental and medical bodies to abortion seeking women.
4.1. Self-help culture and social transformation
Our study found that misoprostol is a commonly known drug in Dar
es Salaam and is available in pharmacies and drug stores across the city.
While never intended for self-induced abortion by the Tanzanian au-
thorities, women and health workers in our study associated mis-
oprostol with abortion more than with any of its other particular uses.
In line with Van der Geest, Hardon and Whyte's approach to pharma-
ceuticals as ‘social things’ (Van der Geest et al., 1996; Whyte, 1992),
our material exemplifies how misoprostol takes on ‘a life of its own’,
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regardless of the intentions from higher regulatory levels who in-
troduced misoprostol for other purposes. In a similar manner, without
legal approval or medical guidance, Brazilian women rebranded mis-
oprostol in the 80s from what was then officially an anti-ulcer drug to
an efficient abortion drug (Zordo, 2016). Zordo et al. argue that the
globalization of medical abortion is first and foremost rooted in in-
itiatives from women themselves as well as from drug vendors in
countries with restrictive abortion laws (Zordo, 2016). This suggests
how a drug is made relevant, also on a global scale, primarily by par-
ticular local and social conditions.
In our study we found that the exchange of misoprostol has estab-
lished networks and social relations that facilitate access to abortion
while circumventing the control and discretion of health workers in the
formal health care institutions set to implement the restrictive law.
What seems to be particularly revealing in our material is the tacit al-
liance that has been formed between women in search of a safe and
undisclosed abortion procedure and drug vendors supplying mis-
oprostol. Whether the motive of the latter is economic gain, conviction
of women's right to abortion or sympathy, they share with the abortion
seeker a clear interest in keeping the transaction secret. This emerges as
a revealing example of how pharmaceuticals and their appropriation by
communities may be socially transformative, and indeed of how mis-
oprostol as an abortion drug is in essence a social phenomenon (Van der
Geest et al., 1996).
Informal medicine markets and ‘self-help cultures’ have commonly
been linked to states that fail to make services accessible to their citi-
zens or fail to pay their health workers sufficient wages to prevent
supplementary income-related activity (Van der Geest et al., 1996;
Whyte et al., 1991; Van der Geest, 1982). However, within the frames
of such informal private markets, agency may be detected and made
manifest through the possibility of negotiating as a customer, rather
than as a patient (Whyte et al., 1991; Reeler, 1996). Our material in-
dicates that misoprostol's many access points and reasonable prices
facilitate an increased potential for the avoidance of the ‘gate-keeping’
power of doctors, and in the process enhanced opportunities for wo-
men's abortion related agency. At the same time the gate-keeping po-
sition of drug vendors should not be underestimated, as emphasized by
Chiarello (2013). In her study on how organizational conditions shape
pharmacists' bioethical decision-making, she points out how retail
pharmacists interact with patients in a different manner than physicians
and other clinic-based health workers. While in one way acting as state
agents, they are often located socially closer to their patients, being
more familiar with their patients' economic needs and social situation
(Chiarello, 2013). In our material the vendors were known to assist
women in need of medical abortion by ensuring access to misoprostol
among other through adjusting prices according to the wealth of the
customer and keeping the information secret.
4.2. Social applicability and empowerment
The centrality of social networks in access to abortion has been well
described in previous studies, including from Sub-Saharan Africa
(Rossier, 2007; Suh, 2014; Coast and Murray, 2016). Women's prag-
matism and agency in the face of at times severe obstacles have been
described. In their study on stigma and abortion in Kenya, Izugbara
et al. found that women consider a safe abortion a procedure that
protects them from poor social outcomes. In practice, this implies ser-
vices found through dependable networks, services that shield women
from the law and conceal their abortions from others (Izugbara et al.,
2015). These findings resonate with the way our participants empha-
sized the importance of secrecy and privacy as key concerns when
seeking abortion. To the women interviewed in Dar es Salaam, mis-
oprostol clearly represented an improved possibility of avoiding public
exposure and abortion related social stigma while obtaining an abortion
at an affordable cost. Women's strategies to keep socially contended
pregnancies secret, and to perform abortion without detection has been
described in several African studies (Bleek, 1981; Johnson-Hanks,
2002; Schuster, 2005; Kebede et al., 2012). With a readily available, far
less invasive and less costly procedure through the use of misoprostol,
the prospect of avoiding public exposure and hence poor social out-
comes is enhanced. In this transition also lies the enhancement of wo-
men's possibility of being in charge of the abortion process itself; se-
curing the drug, ensuring secrecy and privately handling the abortion
procedure. Less interference by outsiders, and a stronger sense of being
in control was located at the core of the stories communicated in the
present study. These processes in turn indicate misoprostol's social
applicability or adaptability. Two recent studies have in a similar
manner indicated that despite the restrictive abortion law and the
continued social stigma that surrounds abortion in Tanzania, it is pos-
sible to pragmatically share information about safe use of misoprostol
(Coeytaux et al., 2014; Kahabuka et al., 2017). Our study adds to this
evidence and suggests that misoprostol has transformed the social ar-
rangements surrounding the access to abortion in Tanzania.
4.3. Barriers, risks and standards of care
While acknowledging misoprostol's transformative implications for
abortion access in Dar es Salaam, our study simultaneously reveals how
experiences related to the use of misoprostol are shaped within existing
social arrangements and hierarchies and indicates a persisting vulner-
ability of women in pursuit of abortion. As was seen above, the highly
restrictive abortion law generates fear of both asking for and providing
comprehensive instructions for the correct use of misoprostol, which in
turn may lead to suboptimal information and thus higher risk of in-
complete abortions. At the same time, we found that without any reg-
ulation or training, information shared about misoprostol was often
incomplete or erroneous. Moreover, while restrictive policies tie the
hands of the drug providers who wish to assist their customers, it si-
multaneously unties the hands of individuals who see an opportunity of
exploiting an illegal market with substantial demand. For instance, the
circulation of substandard or counterfeit drugs in Tanzania is well
known (Almuzaini et al., 2013) and to our study participants “fake”
pills was an element of uncertainty to both women and health workers.
It is important to stress that for women without access to legal and
safe abortion services, the uncertainties involved in entering un-
regulated business with misoprostol providers is forced upon them. The
generally weak position of women in Tanzanian communities, and
being poor and unmarried in particular, only adds to their vulnerability
in an abortion context. Our study demonstrates how fear of stigma
makes it difficult for women to access reliable sources of information
about misoprostol. The literature also shows how informal costs and
social barriers (such as health provider stigma) prevent true access also
to PAC services (Coast and Murray, 2016; Aantjes et al., 2018). This
vulnerability is part of a larger picture of structural violence that
women in our study are subject to. As an example, Silberschmidt and
Rasch have problematized the vulnerability that accompanies female
sexual agency in Dar es Salaam. Within a system of poor access to
sexual and reproductive health services, adolescent's agency puts girls
often unknowingly at risk of exploitation and need for abortion
(Silberschmidt and Rasch, 2001). In line with the thinking of critical
medical anthropologists like Farmer (2004) and Scheper-Hughes
(2004), it is important to consider the lack of influence marginalized
and stigmatized individuals have on the systems that surround them,
despite elements of agency and empowerment. As stressed by Takeshita
(Takeshita et al., 2011), we should be careful not to employ the rhetoric
of ‘choice’ without due consideration of the inequities inherent in wo-
men's positions, be it social, economic or geographic. Bendix et al.
furthermore remind us that sexual and reproductive technologies, such
as misoprostol, ultimately are products linked to larger capitalist eco-
nomic interests as well as to international ideas of social development
and modernization (Bendix et al., 2019). This work reminds us that in
discussions of misoprostol, we need to caution against generalizations
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of user conditions, including standards and safety of care.
5. Conclusion
This study has examined the ways in which misoprostol - a pre-
scription drug officially intended for post-delivery bleeding - is illegally
sold and widely adopted for medical abortion in Dar es Salaam,
Tanzania. The accessibility and common usage of misoprostol may be
an expression of a restrictive law that is not strictly implemented but
which serves important symbolic purposes in a nation where religious
and cultural normative sentiments against abortion are powerful. The
increased availability of the drug may also be seen as an expression of a
silent agreement between women, drug vendors and health workers
that enables women to take increased control over their bodies and
fertility, and reduces inequalities in access to safe abortion among
women. Our study indicates that in Dar es Salaam medical abortion by
the use of misoprostol is a hopeful step forward for women's access and
empowerment in the abortion seeking process. It shows how mis-
oprostol acts as an agent of change in the social relations of abortion –
with implications for the articulation between the power inherent in the
law text, the governmental position, health personnel and drug vendors
on the one hand, and abortion seekers on the other. Yet, our study
shows how misoprostol sold and used illegally compromises the safety
and standardization of the medical procedure, and thus simultaneously
demonstrates the continued vulnerability of abortion seekers within
restrictive social and legal contexts.
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